Quest mentioned it carried out a median of 83,000 COVID-19 molecular checks a day within the third quarter.
MediaNews Group by way of Getty Photographs
Quest Diagnostics on Wednesday signaled an upbeat 2021 revenue as COVID-19 testing volumes surged with the unfold of the Omicron coronavirus variant in the USA.
Quest mentioned it carried out over 120,000 PCR checks per day within the final couple of weeks of 2021, and over 150,000 checks a day initially of this yr.
“We noticed a steep enhance in our volumes within the fourth quarter, notably the final two weeks in December, and it continues into January,” Quest Diagnostics Chief Government Officer Steve Rusckowski mentioned on the annual J.P. Morgan Well being Care convention.
Whereas the COVID-19 testing alternative is predicted to proceed into the primary quarter, demand will finally decline in 2022 in comparison with the final yr, Rusckowski added.
Quest’s feedback echo that of COVID-19 take a look at maker Abbott Laboratories, which has additionally mentioned it expects sturdy testing demand within the close to time period.
Quest mentioned it carried out a median of 83,000 COVID-19 molecular checks a day within the third quarter, ended Sept. 30, pushed by the Delta variant unfold.
Quest now expects 2021 adjusted earnings per share of $14.24, up from its prior forecast of $13.50 to $13.90 per share, given the COVID-19 testing demand surge and a restoration in its base testing enterprise.
It additionally mentioned it expects its 2022 adjusted revenue will exceed the higher finish of its earlier steerage of $7.40 to $8 per share.
Post a Comment